Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users
Miroslav Bačkonja(University of Wisconsin–Madison), G Wolfram(Pfizer (United States)), Kenneth W. Sommerville, Beatrice Setnik, Kyle Matschke(Pfizer (United States)), Lynn R. Webster(Adherent Technologies (United States)), Bimal Malhotra(Pfizer (United States)), Almasa Bass(Pfizer (United States))
Cited by 15
Related Papers
Advances in Neuropathic Pain
|Archives of Neurology|2003|1.2k
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Recommendations for the Management of Herpes Zoster
|Clinical Infectious Diseases|2006|842
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504
Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
|New England Journal of Medicine|2014|331